The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

Papers of particular interest, published recently, have been highlighted as: • Of importance;•• Of major importance

1. 1.
   Hench P. Effects of cortisone in the rheumatic diseases. Lancet. 1950;2(6634):483–4.PubMedGoogle Scholar
2. 2.
   Smolen, J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.Google Scholar
3. 3.
   Sarnes E et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–32.CrossRefPubMedGoogle Scholar
4. 4.
   Kirkham JJ et al. Can a core outcome set improve the quality of systematic reviews?—a survey of the Co-ordinating editors of Cochrane review groups. Trials. 2013;14:21.CrossRefPubMedCentralPubMedGoogle Scholar
5. 5.
   Boers M et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745–53.CrossRefPubMedGoogle Scholar
6. 6.
   Chen YF et al. Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review. J Clin Epidemiol. 2014;67(12):1309–19.CrossRefPubMedGoogle Scholar
7. 7.
   Sheu HM et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136(6):884–90.CrossRefPubMedGoogle Scholar
8. 8.
   Schoepe S et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.CrossRefPubMedGoogle Scholar
9. 9.
   Newell-Price J et al. Cushing’s syndrome. Lancet. 2006;367(9522):1605–17.CrossRefPubMedGoogle Scholar
10. 10.
    Schäcke H, Döcke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.CrossRefPubMedGoogle Scholar
11. 11.
    Tiganescu A et al. 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest. 2013;123(7):3051–60.CrossRefPubMedCentralPubMedGoogle Scholar
12. 12.
    Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol. 1992;5(2):77–80.CrossRefPubMedGoogle Scholar
13. 13.
    Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–6.CrossRefGoogle Scholar
14. 14.
    Vinding GR et al. Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology. 2014;228(3):261–8.CrossRefPubMedGoogle Scholar
15. 15.
    Van der Goes MC et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913–9.CrossRefPubMedGoogle Scholar
16. 16.
    Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol. 1998;80(5):391–4.CrossRefPubMedGoogle Scholar
17. 17.
    Andrews RC et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002;87(12):5587–93.CrossRefPubMedGoogle Scholar
18. 18.
    Quondamatteo F. Skin and diabetes mellitus: what do we know? Cell Tissue Res. 2014;355(1):1–21.CrossRefPubMedGoogle Scholar
19. 19.
    Makrantonaki E, Zouboulis CC. Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci. 2007;1119:40–50.CrossRefPubMedGoogle Scholar
20. 20.
    Aschoff R et al. Evaluation of the atrophogenic potential of hydrocortisone 1 % cream and pimecrolimus 1 % cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832–6.CrossRefPubMedGoogle Scholar
21. 21.
    Schoepe S, Schacke H, Asadullah K. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol. 2011;3(3):175–9.CrossRefPubMedCentralPubMedGoogle Scholar
22. 22.
    Norsgaard H et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–29.CrossRefPubMedCentralPubMedGoogle Scholar
23. 23.
    Hooten J, Hall 3rd R, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Ther Lett. 2014;19(5):1–6.Google Scholar
24. 24.
    Schacke H et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009;158(4):1088–103.CrossRefPubMedCentralPubMedGoogle Scholar
25. 25.
    Sen CK et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763–71.CrossRefPubMedCentralPubMedGoogle Scholar
26. 26.
    Nagareddy PR et al. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol. 2005;289(5):H2144–52.CrossRefPubMedGoogle Scholar
27. 27.
    Holmes CJ et al. Dynamic role of host stress responses in modulating the cutaneous microbiome: implications for wound healing and infection. Adv Wound Care (New Rochelle). 2015;4(1):24–37.CrossRefGoogle Scholar
28. 28.
    Da Silva JA et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93. Epub 2005 Aug 17.CrossRefPubMedCentralPubMedGoogle Scholar
29. 29.
    Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004;28(3):321–6.CrossRefPubMedGoogle Scholar
30. 30.
    Brubaker AL et al. Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age. J Immunol. 2013;190(4):1746–57.CrossRefPubMedCentralPubMedGoogle Scholar
31. 31.
    Saag KG et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23.CrossRefPubMedGoogle Scholar
32. 32.
    van der Goes MC et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015–21.CrossRefPubMedGoogle Scholar
33. 33.
    Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013;63(610):e361–6.CrossRefPubMedCentralPubMedGoogle Scholar
34. 34.
    Carli L et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071–3.CrossRefPubMedGoogle Scholar
35. 35.
    Prokofyeva E, Wegener A, Zrenner E. Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmologica. 2013;91(5):395–405.CrossRefPubMedGoogle Scholar
36. 36.
    Rasanen P et al. Cost-utility of routine cataract surgery. Health Qual Life Outcomes. 2006;4:74.CrossRefPubMedCentralPubMedGoogle Scholar
37. 37.
    Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171–88.CrossRefPubMedGoogle Scholar
38. 38.
    Huscher D et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24.CrossRefPubMedGoogle Scholar
39. 39.
    Hoes JN et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7.CrossRefPubMedCentralPubMedGoogle Scholar
40. 40.
    Mosca M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.CrossRefPubMedCentralPubMedGoogle Scholar
41. 41.
    Lane RJM, Mastaglia FL. Drug-induced myopathies in man. Lancet. 1978;312(8089):562–6.CrossRefGoogle Scholar
42. 42.
    Schakman O et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–72.CrossRefPubMedGoogle Scholar
43. 43.
    Jover JA et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.CrossRefPubMedGoogle Scholar
44. 44.
    Mazlumzadeh M et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.CrossRefPubMedGoogle Scholar
45. 45.
    Spiera RF et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.PubMedGoogle Scholar
46. 46.
    Gabriel SE et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873–8.CrossRefPubMedGoogle Scholar
47. 47.
    Khaleeli AA et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18(2):155–66.CrossRefGoogle Scholar
48. 48.
    Levin OS et al. Steroid myopathy in patients with chronic respiratory diseases. J Neurol Sci. 2014;338(1–2):96–101.CrossRefPubMedGoogle Scholar
49. 49.
    Hosono, O., et al. Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy—comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging. Modern Rheumatology, 2014. 25(2):1–7.Google Scholar
50. 50.
    Batchelor TT et al. Steroid myopathy in cancer patients. Neurology. 1997;48(5):1234–8.CrossRefPubMedGoogle Scholar
51. 51.
    Pereira RMR, de Carvalho JF. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41–4.CrossRefPubMedGoogle Scholar
52. 52.
    LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardpulm Rehabil. 1997;17(2):76–84.CrossRefGoogle Scholar
53. 53.
    Horber FF et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61(1):83–8.CrossRefPubMedGoogle Scholar
54. 54.
    Hansen M et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713–8.CrossRefPubMedCentralPubMedGoogle Scholar
55. 55.
    Laan RF et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119(10):963–8.CrossRefPubMedGoogle Scholar
56. 56.
    Nikitovic M et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659–69.CrossRefPubMedCentralPubMedGoogle Scholar
57. 57.
    Rizzoli, R. and E. Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2014.Google Scholar
58. 58.••
    Compston J et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75(4):392–6. Provides guidelines for the management of osteoporosis.Google Scholar
59. 59.
    Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.CrossRefGoogle Scholar
60. 60.
    Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.CrossRefPubMedGoogle Scholar
61. 61.
    Ton FN et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464–70.CrossRefPubMedGoogle Scholar
62. 62.
    den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233–40.CrossRefGoogle Scholar
63. 63.
    Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23(10):1525–31.CrossRefPubMedGoogle Scholar
64. 64.
    Albaum JM et al. Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol. 2014;21(3):e486–504.PubMedGoogle Scholar
65. 65.
    Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34(9):518–30.CrossRefPubMedCentralPubMedGoogle Scholar
66. 66.
    Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78(11):748–56.CrossRefPubMedGoogle Scholar
67. 67.
    Unizony, S., et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford), 2015.Google Scholar
68. 68.
    Jamilloux Y et al. Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS ONE. 2013;8(7):e68713.CrossRefPubMedCentralPubMedGoogle Scholar
69. 69.
    Kirwan JR et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1415–21.CrossRefPubMedGoogle Scholar
70. 70.••
    Duru, N., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013: 1–9. Provides EULAR recommendations for managing patients on medium-high-dose glucocorticoid therapy.Google Scholar
71. 71.
    Gruvstad E et al. Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Int J Clin Pharmacol Ther. 2014;52(1):15–26. doi: 10.5414/CP201938.CrossRefPubMedGoogle Scholar
72. 72.
    Kazlauskaite R et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–53.CrossRefPubMedGoogle Scholar
73. 73.••
    Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. Provides practical guidance for clinicians for monitoring and managing glucocorticoid-related adverse effects.Google Scholar
74. 74.
    Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest. 2012;122(11):3854–7.CrossRefPubMedCentralPubMedGoogle Scholar
75. 75.
    Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506.CrossRefPubMedGoogle Scholar
76. 76.
    Nwaneri, C., H. Cooper, and D. Bowen-Jones, Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease, 2013.Google Scholar
77. 77.
    Wassenberg S et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371–80.CrossRefPubMedGoogle Scholar
78. 78.
    van Everdingen AA et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12.CrossRefPubMedGoogle Scholar
79. 79.
    Ha Y et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011;20(10):1027–34.CrossRefPubMedGoogle Scholar
80. 80.
    Dasgupta B et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–90.CrossRefGoogle Scholar
81. 81.
    Dasgupta B et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.CrossRefGoogle Scholar
82. 82.
    Hancock AT et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014;186(13):E495–501.CrossRefPubMedCentralPubMedGoogle Scholar
83. 83.
    Uddhammar A et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737–42.PubMedGoogle Scholar
84. 84.
    Aviña-Zubieta JA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology. 2013;52(1):68–75.CrossRefPubMedGoogle Scholar
85. 85.
    Mazzantini M et al. Adverse events during long-term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39(3):552–7.CrossRefPubMedGoogle Scholar
86. 86.
    Hafström I et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis—a randomized study. J Rheumatol. 2007;34(9):1810–6.PubMedGoogle Scholar
87. 87.
    Hafner F et al. Endothelial function and carotid intima-media thickness in giant-cell arteritis. Eur J Clin Investig. 2014;44(3):249–56.CrossRefGoogle Scholar
88. 88.
    Souverein PC et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.CrossRefPubMedCentralPubMedGoogle Scholar
89. 89.
    Tomasson G et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160(2):73–80.CrossRefPubMedCentralPubMedGoogle Scholar
90. 90.
    Kirwan J et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):688–95.CrossRefPubMedCentralPubMedGoogle Scholar
91. 91.
    Bakker MF et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–39.CrossRefPubMedGoogle Scholar
92. 92.
    Hoes JN et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.CrossRefPubMedGoogle Scholar
93. 93.
    Reynolds RM et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh type 2 diabetes study. Eur J Endocrinol. 2012;166(5):861–8.CrossRefPubMedCentralPubMedGoogle Scholar
94. 94.
    Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–7.CrossRefPubMedGoogle Scholar
95. 95.
    Ninan J et al. Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol. 2011;38(10):2215–7.CrossRefPubMedGoogle Scholar
96. 96.
    Nadkarni S et al. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014;114(2):242–8.CrossRefPubMedGoogle Scholar
97. 97.
    Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.CrossRefPubMedGoogle Scholar
98. 98.
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMedGoogle Scholar
99. 99.
    Harrison MJ et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008;35(4):592–602.PubMedGoogle Scholar
100. 100.
     Buitinga L et al. Comparative responsiveness of the EuroQol-5D and short form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res. 2012;64(6):826–32.CrossRefGoogle Scholar
101. 101.
     Gaujoux-Viala C et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(9):1478–83.CrossRefPubMedGoogle Scholar
102. 102.
     Marra CA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.CrossRefPubMedGoogle Scholar
103. 103.•
     Moller A, Sartipy U. Long-term health-related quality of life following surgery for lung cancer. Eur J Cardiothorac Surg. 2012;41(2):362–7. Demonstrates EQ-5D is responsive to AEs.Google Scholar
104. 104.
     Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125–9.CrossRefPubMedGoogle Scholar
105. 105.
     NICE, Guide to the methods of technology appraisal 2013. Process and methods guides. 2013: London, UK.Google Scholar
106. 106.
     Heather EM et al. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-alpha drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics. 2014;32(2):109–34.CrossRefPubMedGoogle Scholar